IPO - Cogent Biosciences, Inc.

Form Type: 424B5

Filing Date: 2025-07-09

Corporate Action: Ipo

Type: New

Accession Number: 000119312525157121

Filing Summary: Cogent Biosciences, Inc. is offering 22,222,223 shares of its common stock, with a public offering price of $9.00 per share, totaling $200,000,007. After underwriting discounts, the proceeds to Cogent amount to approximately $188,000,007. The underwriters have the option to purchase an additional 3,333,333 shares within 30 days of this prospectus supplement. The company's stock is traded on the Nasdaq Global Select Market under the symbol 'COGT'. The offering is part of a registration statement filed as an automatic shelf registration on Form S-3ASR, effective since February 10, 2023. The document includes risk factors, the use of proceeds for development and commercialization of their lead candidate, bezuclastinib, which is aimed at treating systemic mastocytosis and gastrointestinal tumors. Positive results from the SUMMIT clinical trial indicated significant effectiveness and plans for an NDA submission to the FDA by the end of 2025 are in place. Cash and equivalents as of June 30, 2025, were approximately $237.8 million. The prospectus urges investors to review risks and performance data before investing.